Companies /Healthcare

Alcon Inc

NYSE: ALC Medical Instruments & Supplies
$73.79
▼ $0.33 (−0.45%) today
Markets open · 2:34pm ET

24/7 Wall St. View

ALC at a Glance

Valuation
Market cap
$35.6B
P/E ratio
54.1
Dividend yield
0.49%
Profitability
Revenue (TTM)
$11.0B
Profit margin
6.1%
EPS (TTM)
$1.37
Price
52-week range
$62 – $87
24/7 target
$118.47
Street target
$81.46

Headquartered in Chemin De Blandonnet 8, Geneva Fiscal year ends December NYSE: ALC alcon.com

About Alcon

Alcon is an eye care company that researches, develops, manufactures and sells products through two reportable segments, Surgical and Vision Care. It also provides services, training, education and technical support to eye care professionals.

The Surgical segment serves cataract, vitreoretinal, refractive laser and glaucoma surgery. It includes:
- Implantables: intraocular lenses such as PanOptix Pro
- Consumables used in these procedures
- Equipment: the UNITY vitreoretinal/cataract system, the UNITY M microscope, Valeda photobiomodulation for dry AMD (from the 2025 LumiThera acquisition) and Cylite diagnostics

The Vision Care segment includes:
- Daily disposable, reusable and color-enhancing contact lenses
- Cell therapies to treat ocular diseases
- Ocular health products: dry eye treatments such as Tryptyr and Systane, allergy and glaucoma products, contact lens care, ocular vitamins and redness relievers such as the newly FDA-approved BRYTLY

Alcon has been expanding into biopharmaceuticals and cell therapy. This includes Aurion Biotech, acquired in 2025 for a corneal cell therapy candidate, and the October 2026 acquisition of Neurotech Pharmaceuticals, which added ENCELTO, an FDA-approved cell therapy for MacTel, to its retina portfolio.

The company serves patients in over 140 countries and territories with more than 25,000 associates. The United States accounts for roughly 46% of net sales. Alcon reports under IFRS and is listed on SIX and NYSE. Updated

Latest Activity

ALCAlcon
Q3 2026
EPS
$0.91
est $0.89+2.3%
Revenue
$2.74B
est $2.74B-0.2%

Margins are carrying Alcon: gross margin expanded to 59.7% from 56.3%, helped by $58 million in tariff refunds, enough to beat on earnings even with revenue landing just under estimates. Management tightened full-year guidance to about 6% constant-currency sales growth and 12% to 14% core EPS growth, so the durability of that margin lift is the thing to track.

Quarterly EPS — reported vs estimate

ALC Coverage

Frequently Asked Questions

What does Alcon do?

Alcon is an eye care company that researches, develops, manufactures and sells products through two reportable segments, Surgical and Vision Care. It also provides services, training, education and technical support to eye care professionals.

What is the ALC stock price target?

24/7 Wall St.'s 12-month price target for ALC is $118.47, rated Buy. The Wall Street consensus target is $81.46. ALC price prediction →